Why the study?
To present a summary of the evidence and outline safety recommendations regarding anticoagulant and antiplatelet agents for cervical medial branch procedures.
Should therapeutic anticoagulant and antiplatelet agents be discontinued prior to cervical medial branch procedures to prevent hemorrhagic risks?
Should therapeutic anticoagulant and antiplatelet agents be discontinued prior to cervical medial branch procedures to prevent hemorrhagic risks?
Therapeutic anticoagulation and antiplatelet agents should be discontinued prior to cervical medial branch radiofrequency neurotomy to avoid serious hemorrhagic complications.
This series of FactFinders presents a brief summary of the evidence and outlines recommendations regarding the safety of anticoagulant and antiplatelet agents for cervical medial branch blocks and cervical medial branch radiofrequency neurotomy. The evidence in support of the following facts is presented: (1) In patients maintained on therapeutic anticoagulant (AC) and/or antiplatelet (AP) therapy, for whom cervical medial branch blocks (CMBBs) are being considered, there is strong evidence to guide decisions on continuing or discontinuing these AC/AP agents in preparation for the procedure. (2) Therapeutic anticoagulation (AC) and antiplatelet (APT) agents should be discontinued prior to cervical medial branch radiofrequency neurotomy (CMBRFN) due to serious hemorrhagic risks.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted a review in Patients on therapeutic anticoagulant and/or antiplatelet therapy undergoing cervical medial branch procedures. Anticoagulant and antiplatelet agents was evaluated on Safety and hemorrhagic risks. Therapeutic anticoagulation and antiplatelet agents should be discontinued prior to cervical medial branch radiofrequency neurotomy due to serious hemorrhagic risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: